Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- Evaluation and management of overactive bladder: strategies for optimizing care.Res Rep Urol. 2016; 8: 113-122
- Prevalence and burden of overactive bladder in the United States.World J Urol. 2003; 20: 327-336
- Vulnerable elderly patients and overactive bladder syndrome.Drugs Aging. 2010; 27: 697-713
- Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.Neurourol Urodyn. 2015; 34: 224-230
- Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence.N Engl J Med. 2012; 367: 1803-1813
- Improving recruitment of older people to research through good practice.Age Ageing. 2011; 40: 659-665
- OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women. A randomized clinical trial.JAMA. 2016; 316: 1366-1374
- The development of a comorbidity index with physical function as the outcome.J Clin Epidemiol. 2005; 58: 595-602
- An Overactive Bladder symptoms and Health-Related Quality of Life Short-Form: validation of the OAB-q SF.Neurourol Urodyn. 2015; 34: 255-263
- A severity index for epidemiological surveys of female urinary incontinence comparison with 48-hour pad-weighing tests.Neurourol Urodyn. 2000; 19: 137-145
- Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory.Neurourol Urodyn. 1995; 14: 131-139
- Multi-attribute and single-attribute utility functions for the health utilities index mark 3 system.Med Care. 2002; 40: 113-128
- Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment.Phys Ther. 2005; 85: 1008-1019
- Validation of two global impression questionnaires for incontinence.Am J Obstet Gynecol. 2003; 189: 98-101
- Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).Neurourol Urodyn. 2009; 28: 416-421
- Incontinence in the frail elderly: report from the Fourth International Consultation on Incontinence.Neurourol Urodyn. 2010; 29: 165-178
- The aging lower urinary tract.J Urol. 2006; 175: S11-S15
- Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.Med Care. 2003; 41: 582-592
- Determining the importance of change in the overactive bladder questionnaire.J Urol. 2006; 176: 627-632
- Predictors of response to intradetrusor botulinum toxin-A Injections in patients with idiopathic overactive bladder.Adv Urol. 2009; : 328364
- Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?.Urology. 2005; 66: 746-750
- Urinary incontinence in degenerative spinal disease.Acta Chir Traumatol Cech. 2011; 78: 67-70
- Low back pain and urinary incontinence. A hypothetical relationship.Spine. 1994; 19: 1148-1152
- Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction.Urology. 2002; 60: 598-602
- Urinary tract infection: self-reported incidence and associated costs.Ann Epidemiol. 2000; 10: 509-515
- Prevalence and factors associated with urinary tract infections (UTIs) in very old women.Arch Gerontol and Geriatrics. 2010; 50: 132-135
- Urinary retention in female OAB after intravesical Botox injection: who is really at risk?.Int Urogynecol J. 2017; 28: 845-850
The Eunice Kennedy Shriver National Institute of Child Health and Human Development sponsored this Pelvic Floor Disorders Network (PFDN) study. As Project Scientist for the PFDN during study initiation and data collection, Susie Meikle, MD, played a role in the design, conduct, and data collection for the study. Lisa Halvorson, MD, Program Officer for the PFDN, oversaw the administration of funds to support this study.
Dr. Komesu was supported by Co-PI grant 1R01AT007171, National Center Complementary and Integrative Health, National Institutes of Health. Dr. Richter was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (National Institutes of Health) during the conduct of the study; grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development; grants from National Institutes of Health/Washington University; grants from Patient-Centered Outcomes Research Institute/Brown University; grants from NIAID/National Institutes of Health/Department of Homeland Security; grants from University of Texas Southwestern; grants and personal fees from Pelvalon; personal fees from UpToDate, Astellas, Ferring; Kimberly Clark, and Springer; grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development; and grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development/Yale outside the submitted work. All authors were supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development for this study.
The authors report no conflict of interest.
Cite this article as: Komesu YM, Amundsen CL, Richter HE, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. Am J Obstet Gynecol 2018;218:111.e1-9.